Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Preclinical data on human papillomavirus, Lassa fever therapy reported
August 25th, 2005
SciClone Pharmaceuticals, Inc. (SCLN) announced that its immunomodulatory compound SCV-07 was effective in preclinical studies, significantly reducing lesions in a model of human papillomavirus (HPV) and increasing survival in a model of Lassa fever. These data were presented at the International Union of Microbiological Societies (IUMS) conference in San Francisco, California. The HPV model study was conducted by Neil D. Christensen, PhD, associate professor of pathology, and microbiology and immunology at Pennsylvania State University. The Lassa fever model study was conducted in the laboratory of Dr. C.J. Peters, professor, Department of Pathology, University of...
Source: Women's Health Weekly (2005-08-25)
|
